Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 20,694 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Severe Acute Alcoholic Hepatitis
Interventions: ELAD, Standard of Care treatment; Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more

Conditions: Bone Health
Interventions: exercise, exercise and calcium; Behavioral
Lead sponsor: Creighton University; Other
Eligibility: 9 Years to 9 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Kidney Transplant
Interventions: IVIG and Rituximab; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoxemia
Interventions: Capnography; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anemia of Prematurity (AOP)
Interventions: Restrictive transfusions based on SCOR assessment, Liberal transfusions; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 3 Days
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Hodgkin Lymphoma
Interventions: brentuximab vedotin, nivolumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 13
States / cities: Duarte, California • Stanford, California • Boston, Massachusetts + 10 more

Conditions: Cancer, Immune-related Adverse Event
Interventions: Medical chart review; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Surgery, Anesthesia, Pain
Interventions: General Anesthesia, Deep Sedation; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury
Interventions: Early RASi restart strategy, Usual Care; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: Optical Blood Pressure Monitoring Device (Aktiia G1); Device
Lead sponsor: Nucor; Industry
Eligibility: 25 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Heart Failure, Hypertension
Interventions: PAL2, PHARM-PAL2; Behavioral · Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Blood Loss, Anatomic Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Transfusion, Tranexamic Acid
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Arterial Hypertension
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 38 more

Conditions: Spinal Cord Injuries, Autonomic Imbalance, Autonomic Dysreflexia, Orthostatic; Hypotension, Neurogenic
Interventions: Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia, Transcutaneous spinal cord stimulation; Diagnostic Test · Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 30 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neurofibromatosis 1, Neurofibroma, Atypical Neurofibroma, Atypical Neurofibromatosis, Plexiform Neurofibroma, Von Recklinghausen Disease
Interventions: Whole Body MRI; Diagnostic Test
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Lymphoma
Interventions: aldesleukin, allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, fludarabine phosphate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions: Durvalumab, Sirolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Inflammatory Bowel Diseases
Interventions: Infliximab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Thrombosis, Type 2 Diabetes Mellitus
Interventions: omega-3 and -6 fatty acids and their 12-LOX oxylipins; Other
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania

Conditions: Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart, Positron Emission Tomography; Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography; Genetic · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 180
States / cities: Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more

Conditions: Acute Coronary Syndrome
Interventions: intensive LDL-lowering therapy, standard statin monotherapy; Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 31 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Dallas, Texas

Conditions: Hypogonadism, Male
Interventions: Testosterone Undecanoate; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Northbrook, Illinois

Conditions: Menopause, Elevated Blood Pressure, Hypertension, Endothelial Dysfunction
Interventions: Blueberry Powder, Placebo Powder; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Search by objective public record fields.

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Study to Determine How Exercise and Calcium Affect Pubertal Bone

Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

Does Capnography Prevent Hypoxemia During Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound?

Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

Intravenous Sedation Versus General Anesthesia in Patients Undergoing Minor Gynecologic Surgery

A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

A Comprehensive Optical Blood Pressure Assessment Tool to Identify Cases of Unscreened Hypertension Across an Active Population in the U.S.

Project 2: ACHIEVE- HF

Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Safety of Reduced Infliximab Infusion Time

Fatty Acid Regulation of Platelet Function in Diabetes

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure